Abstract
Over half of patients with type 2 diabetes (T2D) are unable to achieve blood glucose targets despite therapeutic compliance, significantly increasing their risk of long-term complications. Discovering ways to identify and properly treat these individuals is a critical problem in the field. The arachidonic acid metabolite, prostaglandin E2 (PGE2), has shown great promise as a biomarker of β-cell dysfunction in T2D. PGE2 synthesis, secretion, and downstream signaling are all upregulated in pancreatic islets isolated from T2D mice and human organ donors. In these islets, preventing β-cell PGE2 signaling via a prostaglandin EP3 receptor antagonist significantly improves their glucose-stimulated and hormone-potentiated insulin secretion response. In this clinical cohort study, 167 participants, 35 non-diabetic, and 132 with T2D, were recruited from the University of Wisconsin Hospital and Clinics. At enrollment, a standard set of demographic, biometric, and clinical measurements were performed to quantify obesity status and glucose control. C reactive protein was measured to exclude acute inflammation/illness, and white cell count (WBC), erythrocyte sedimentation rate (ESR), and fasting triglycerides were used as markers of systemic inflammation. Finally, a plasma sample for research was used to determine circulating PGE2 metabolite (PGEM) levels. At baseline, PGEM levels were not correlated with WBC and triglycerides, only weakly correlated with ESR, and were the strongest predictor of T2D disease status. One year after enrollment, blood glucose management was assessed by chart review, with a clinically-relevant change in hemoglobin A1c (HbA1c) defined as ≥0.5%. PGEM levels were strongly predictive of therapeutic response, independent of age, obesity, glucose control, and systemic inflammation at enrollment. Our results provide strong support for future research in this area.
Funder
United States Department of Veterans Affairs
UW-Madison Office of the Vice Chancellor for Research and Graduate Education and the Wisconsin Alumni Research Foundation
National Institutes of Health
PhRMA Foundation
UW Institute for Clinical and Translational Research
Subject
Molecular Biology,Biochemistry,Endocrinology, Diabetes and Metabolism
Reference68 articles.
1. (2022, October 01). Center for Diseease Control and Prevention, National Diabetes Statistics Report Website, Available online: https://www.cdc.gov/diabetes/data/statistics-report/index.html.
2. Failure to reach target glycated a1c levels among patients with diabetes who are adherent to their antidiabetic medication;Juarez;Popul. Health Manag.,2014
3. Bacos, K., Gillberg, L., Volkov, P., Olsson, A.H., Hansen, T., Pedersen, O., Gjesing, A.P., Eiberg, H., Tuomi, T., and Almgren, P. (2016). Blood-based biomarkers of age-associated epigenetic changes in human islets associate with insulin secretion and diabetes. Nat. Commun., 7.
4. Biomarkers of beta-Cell Stress and Death in Type 1 Diabetes;Mirmira;Curr. Diabetes Rep.,2016
5. Precision medicine: The future in diabetes care?;Scheen;Diabetes Res. Clin. Pract.,2016
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献